Cargando…
Impact of cannabis use on Schizo-affective disorder
INTRODUCTION: Schizoaffective disorder (SAD) is a nosographic entity characterized by an association of schizophrenic symptoms with thymic episodes. Addictive substance abuse behaviours precede or appear concomitantly with thymic and/or schizophrenic symptoms for the majority of patients. OBJECTIVES...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660881/ http://dx.doi.org/10.1192/j.eurpsy.2023.1225 |
_version_ | 1785137853385146368 |
---|---|
author | Zbidi, M. Bouali, W. Haouari, W. Kacem, M. Khouadja, S. Zarrouk, L. |
author_facet | Zbidi, M. Bouali, W. Haouari, W. Kacem, M. Khouadja, S. Zarrouk, L. |
author_sort | Zbidi, M. |
collection | PubMed |
description | INTRODUCTION: Schizoaffective disorder (SAD) is a nosographic entity characterized by an association of schizophrenic symptoms with thymic episodes. Addictive substance abuse behaviours precede or appear concomitantly with thymic and/or schizophrenic symptoms for the majority of patients. OBJECTIVES: The objective of our work was to specify the sociodemographic ,clinical and therapeutic characteristics of this population and to compare them to a group of schizophrenic patients who do not use cannabis. METHODS: This is a retrospective descriptive study of patients with Schizoaffective Disorder (SAD) meeting the criteria of the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, 5th Version (DSM-5), hospitalized between January 2015 and December 2021 in the psychiatry department of the EPS Tahar Sfar Mahdia. RESULTS: Our sample was composed of two groups: A first group formed by patients with a positive toxicological assessment to tetra-hydro-cannabinol (n=14) and a second group witha negative toxicological assessment (n=36). In SAD subjects using cannabis, the average age at first hospitalization was younger (27.5 years) than in the other groups, hospitalization was earlier (27.27 vs 33.58; p=0.04), the duration in number of days of hospitalization was greater (29.33 vs. 24.67; p=0.02) and they had required during their hospital stay a higher dosage of antipsychotics in equivalent doses of chlorpromazine (723 vs 603; p=0.04). There was a significant difference (p ≤ 0.04) in the psychometric scales (BPRS, SAPS and SANS) in favour of patients who did not use cannabis. CONCLUSIONS: The deleterious psychic effects of chronic cannabis use have long been suspected for a long time. Patients followed for SAD present more frequently than the reference population addictive behaviours towards cannabis which is associated with many negative events affecting clinical symptomatology, evolution, prognosis and therapeutic response. DISCLOSURE OF INTEREST: None Declared |
format | Online Article Text |
id | pubmed-10660881 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106608812023-07-19 Impact of cannabis use on Schizo-affective disorder Zbidi, M. Bouali, W. Haouari, W. Kacem, M. Khouadja, S. Zarrouk, L. Eur Psychiatry Abstract INTRODUCTION: Schizoaffective disorder (SAD) is a nosographic entity characterized by an association of schizophrenic symptoms with thymic episodes. Addictive substance abuse behaviours precede or appear concomitantly with thymic and/or schizophrenic symptoms for the majority of patients. OBJECTIVES: The objective of our work was to specify the sociodemographic ,clinical and therapeutic characteristics of this population and to compare them to a group of schizophrenic patients who do not use cannabis. METHODS: This is a retrospective descriptive study of patients with Schizoaffective Disorder (SAD) meeting the criteria of the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, 5th Version (DSM-5), hospitalized between January 2015 and December 2021 in the psychiatry department of the EPS Tahar Sfar Mahdia. RESULTS: Our sample was composed of two groups: A first group formed by patients with a positive toxicological assessment to tetra-hydro-cannabinol (n=14) and a second group witha negative toxicological assessment (n=36). In SAD subjects using cannabis, the average age at first hospitalization was younger (27.5 years) than in the other groups, hospitalization was earlier (27.27 vs 33.58; p=0.04), the duration in number of days of hospitalization was greater (29.33 vs. 24.67; p=0.02) and they had required during their hospital stay a higher dosage of antipsychotics in equivalent doses of chlorpromazine (723 vs 603; p=0.04). There was a significant difference (p ≤ 0.04) in the psychometric scales (BPRS, SAPS and SANS) in favour of patients who did not use cannabis. CONCLUSIONS: The deleterious psychic effects of chronic cannabis use have long been suspected for a long time. Patients followed for SAD present more frequently than the reference population addictive behaviours towards cannabis which is associated with many negative events affecting clinical symptomatology, evolution, prognosis and therapeutic response. DISCLOSURE OF INTEREST: None Declared Cambridge University Press 2023-07-19 /pmc/articles/PMC10660881/ http://dx.doi.org/10.1192/j.eurpsy.2023.1225 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Zbidi, M. Bouali, W. Haouari, W. Kacem, M. Khouadja, S. Zarrouk, L. Impact of cannabis use on Schizo-affective disorder |
title | Impact of cannabis use on Schizo-affective disorder |
title_full | Impact of cannabis use on Schizo-affective disorder |
title_fullStr | Impact of cannabis use on Schizo-affective disorder |
title_full_unstemmed | Impact of cannabis use on Schizo-affective disorder |
title_short | Impact of cannabis use on Schizo-affective disorder |
title_sort | impact of cannabis use on schizo-affective disorder |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660881/ http://dx.doi.org/10.1192/j.eurpsy.2023.1225 |
work_keys_str_mv | AT zbidim impactofcannabisuseonschizoaffectivedisorder AT boualiw impactofcannabisuseonschizoaffectivedisorder AT haouariw impactofcannabisuseonschizoaffectivedisorder AT kacemm impactofcannabisuseonschizoaffectivedisorder AT khouadjas impactofcannabisuseonschizoaffectivedisorder AT zarroukl impactofcannabisuseonschizoaffectivedisorder |